S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells

S100A8 and S100A9 function as essential factors in inflammation and also exert antitumor or tumorigenic activity depending on the type of cancer. Chronic eosinophilic leukemia (CEL) is a rare hematological malignancy having elevated levels of eosinophils and characterized by the presence of the FIP1L1-PDGFRA fusion gene. In this study, we examined the pro-apoptotic mechanisms of S100A8 and S100A9 in FIP1L1-PDGFRα+ eosinophilic cells and hypereosinophilic patient cells. S100A8 and S100A9 induce apoptosis of the FIP1L1-PDGFRα+ EoL-1 cells via TLR4. The surface TLR4 expression increased after exposure to S100A8 and S100A9 although total TLR4 expression decreased. S100A8 and S100A9 suppressed the FIP1L1-PDGFRα-mediated signaling pathway by downregulating FIP1L1-PDGFRα mRNA and protein expression and triggered cell apoptosis by regulating caspase 9/3 pathway and Bcl family proteins. S100A8 and S100A9 also induced apoptosis of imatinib-resistant EoL-1 cells (EoL-1-IR). S100A8 and S100A9 blocked tumor progression of xenografted EoL-1 and EoL-1-IR cells in NOD-SCID mice and evoked apoptosis of eosinophils derived from hypereosinophilic syndrome as well as chronic eosinophilic leukemia. These findings may contribute to a progressive understanding of S100A8 and S100A9 in the pathogenic and therapeutic mechanism of hematological malignancy.

[1]  Shue Li,et al.  S100A9 Regulates MDSCs-Mediated Immune Suppression via the RAGE and TLR4 Signaling Pathways in Colorectal Carcinoma , 2019, Front. Immunol..

[2]  C. Pathak,et al.  Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer. , 2019, International journal of biological macromolecules.

[3]  G. Tanriover,et al.  Presence of S100A8/Gr1‐Positive Myeloid‐Derived Suppressor Cells in Primary Tumors and Visceral Organs Invaded by Breast Carcinoma Cells , 2018, Clinical breast cancer.

[4]  V. Čokić,et al.  TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms , 2018, Cellular Oncology.

[5]  D. H. Kim,et al.  Chemotactic effect of S100A8 and S100A9 on human eosinophilic leukemia cells, EoL-1 through TLR4 , 2018, Molecular & Cellular Toxicology.

[6]  Jian Ma,et al.  S100A8/A9 in Inflammation , 2018, Front. Immunol..

[7]  Qingsong Liu,et al.  Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia. , 2018, European journal of medicinal chemistry.

[8]  K. Iwai,et al.  Crucial Role of Linear Ubiquitin Chain Assembly Complex–Mediated Inhibition of Programmed Cell Death in TLR4-Mediated B Cell Responses and B1b Cell Development , 2018, The Journal of Immunology.

[9]  S. Hua,et al.  Immunological Approaches Towards Cancer and Inflammation: A Cross Talk , 2018, Front. Immunol..

[10]  M. Herzberg,et al.  Calprotectin and the Initiation and Progression of Head and Neck Cancer , 2018, Journal of dental research.

[11]  A. Zarbock,et al.  Alarmin S100A8 Activates Alveolar Epithelial Cells in the Context of Acute Lung Injury in a TLR4-Dependent Manner , 2017, Front. Immunol..

[12]  Yang Xu,et al.  Monophosphoryl lipid a attenuates radiation injury through TLR4 activation , 2017, Oncotarget.

[13]  L. Zitvogel,et al.  Nutrition, inflammation and cancer , 2017, Nature Immunology.

[14]  D. Viemann,et al.  S100-alarmin-induced innate immune programming protects newborn infants from sepsis , 2017, Nature Immunology.

[15]  L. Gil,et al.  S100A9 induces differentiation of acute myeloid leukemia cells through TLR4. , 2017, Blood.

[16]  A. Reiter,et al.  Myeloid neoplasms with eosinophilia. , 2017, Blood.

[17]  M. Lai,et al.  S100A8+ stroma cells predict a good prognosis and inhibit aggressiveness in colorectal carcinoma , 2017, Oncoimmunology.

[18]  Yuexiang Wang,et al.  Lyn mediates FIP1L1-PDGFRA signal pathway facilitating IL-5RA intracellular signal through FIP1L1-PDGFRA/JAK2/Lyn/Akt network complex in CEL , 2016, Oncotarget.

[19]  D. Boger,et al.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists. , 2016, Journal of medicinal chemistry.

[20]  Bing Li,et al.  Long-term outcomes of imatinib in patients with FIP1L1/PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China , 2016, Oncotarget.

[21]  A. Kitao,et al.  Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment , 2016, Oncogene.

[22]  Ann Lohner.  "Long-Term Exposure" , 2016 .

[23]  K. Jirström,et al.  S100A9 expressed in ER−PgR− breast cancers induces inflammatory cytokines and is associated with an impaired overall survival , 2015, British Journal of Cancer.

[24]  Seung Yeop Baek,et al.  House Dust Mite Allergen Regulates Constitutive Apoptosis of Normal and Asthmatic Neutrophils via Toll-Like Receptor 4 , 2015, PloS one.

[25]  A. Reiter,et al.  F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance , 2015, Leukemia.

[26]  David J Weber,et al.  S100 proteins in cancer , 2015, Nature Reviews Cancer.

[27]  David J Weber,et al.  S 100 proteins in cancer , 2015 .

[28]  C. Fegan,et al.  Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. , 2014, Journal of proteome research.

[29]  D. Tang,et al.  S100A8 Contributes to Drug Resistance by Promoting Autophagy in Leukemia Cells , 2014, PloS one.

[30]  Nikhil S. Joshi,et al.  TLR4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A Differentially Regulate Effector and Memory CD8+ T Cell Differentiation , 2014, The Journal of Immunology.

[31]  T. Lion,et al.  Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. , 2014, Experimental hematology.

[32]  Honglin Li,et al.  Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin , 2014, Molecular Cancer.

[33]  A. Reiter,et al.  Oncostatin M is a FIP1L1/PDGFRA‐dependent mediator of cytokine production in chronic eosinophilic leukemia , 2013, Allergy.

[34]  Yongbin Wu,et al.  Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor α and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells , 2012, Clinical Cancer Research.

[35]  A Bouamrani,et al.  Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients , 2011, Leukemia.

[36]  Carolyn L. Geczy,et al.  Inflammation-associated S100 proteins: new mechanisms that regulate function , 2011, Amino Acids.

[37]  T. Ikezoe,et al.  Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene , 2010, Leukemia.

[38]  J. Garin,et al.  Expression of S100A8 in Leukemic Cells Predicts Poor Survival in De Novo AML Patients. , 2009 .

[39]  Yanli Jin,et al.  Triptolide abrogates oncogene FIP1L1‐PDGFRα addiction and induces apoptosis in hypereosinophilic syndrome , 2009, Cancer science.

[40]  Sangdun Choi,et al.  Toll-like receptor signal transduction , 2007, Experimental & Molecular Medicine.

[41]  Thomas C. Mitchell,et al.  The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4 , 2007, Science.

[42]  A. Tefferi,et al.  Eosinophilia: secondary, clonal and idiopathic , 2006, British journal of haematology.

[43]  D. Gary Gilliland,et al.  The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management , 2004 .

[44]  S. Schrier,et al.  The FIP 1 L 1-PDGFR fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia : implications for diagnosis , classification , and management , 2004 .

[45]  R. Osborne.  Cross talk. , 1996, Nursing standard (Royal College of Nursing (Great Britain) : 1987).